Everest Medicines’ Partner Calliditas Presents New Data from the NefIgArd Phase 3 Trial at the 17th International Symposium on IgA Nephropathy Tokyo 2023

SHANGHAI, Oct. 4, 2023 /PRNewswire/ — Everest Medicines’ (HKEX 1952.HK, “Everest”, or the “Company”) partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) presented new biomarker and subgroup analyses from Nefecon®’s Phase 3 NefIgArd study in both…